Evidence map›Paper›PMID 41286377›Full record

ArticleClinical and experimental medicine2025

Study on the regulation of Treg cell infiltration by EZH2 through CXCR4/CXCL12 in diffuse large B-cell lymphoma.

Hongxia Wang, Dongyu Liang, Yu Qian, Yajun Jiang, Rong Yang, Hong Yin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hongxia WangDepartments of Oncology, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou, 215100, China.
Dongyu LiangDepartment of Central Laboratory, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, 201800, China.
Yu QianDepartments of Oncology, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou, 215100, China.
Yajun JiangDepartment of Hematology, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, No.1 Chengbei Road, Shanghai, 201800, China. jiangyajun-2001@163.com.
Rong YangDepartment of Pathology, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, 201800, China.
Hong YinDepartments of Oncology, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou, 215100, China. hongyin_74@126.com.

Funding

Natural Science Research Project of Jiading Distric JDKW-2025-0024Suzhou 2023 annual science and technology development plan, Suzhou SKY2023152
6 · The paper itself

Abstract

Enhancer of Zeste Homolog 2 (EZH2) is an important methyltransferase, which is overexpressed in a variety of tumors and is involved in promoting tumor growth and immune escape. Both EZH2 and C-X-C chemokine receptor type 4 (CXCR4) exhibit high-level expression in the germinal centers of lymph nodes. However, it remains unclear whether there exists a synergistic relationship between these two molecules. Our study found that approximately 90.7% of cases of diffuse large B-cell lymphoma (DLBCL) exhibited medium-to-high intensity expression of both EZH2 and CXCR4. CXCR4 and C-X-C motif chemokine ligand 12 (CXCL12) are a pair of receptor-ligands, which are related to tumor invasion and migration and immune cell infiltration in the tumor background. Our study found that the expression intensity of EZH2 and CXCR4 in CXCL12 + group DLBCL and the level of Treg cell infiltration were higher than those in CXCL12- group. In CXCL12 + DLBCL, EZH2 might regulate the infiltration level of Treg cells through CXCR4/CXCL12. In the in vitro experiment of co-culture of human Peripheral Blood Mononuclear Cells (PBMCs) and DLBCL cell lines, we also observed that under the chemotactic effect of CXCL12, the proportion of Treg cells in the oe-EZH2 group was higher than that in the oe-NC group. In DLBCL tumor cells of the oe-EZH2 group, the expression of CXCR4 could be upregulated CXCR4 through the downregulation of miR-9. Subsequently, the upregulated CXCR4 binds to the exogenous CXCL12, thereby increasing the differentiation ratio of Treg cells in PBMCs. In the subcutaneous transplanted tumor model of C-NKG mice with human T cell immune function, the sh-EZH2 group had less Treg cell infiltration in the tumor and lower tumor cell activity compared with the sh-NC group. In summary, our study found that the EZH2/miR-9/CXCR4 pathway participates in the occurrence and development of DLBCL. Specifically, high-expression EZH2 recruits the infiltration of Treg cells within the chemotactic DLBCL microenvironment via the upregulated CXCR4/CXCL12 axis. This research provides novel evidence for elucidating the immune escape mechanism of DLBCL. EZH2 and its associated signaling cascades hold the potential to serve as promising targets for the immunotherapy of DLBCL.

Indexed as

Chemokine CXCL12Enhancer of Zeste Homolog 2 ProteinLymphoma, Large B-Cell, DiffuseReceptors, CXCR4T-Lymphocytes, RegulatoryAdultAgedAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMiddle AgedChemokine CXCL12CXCL12 protein, humanCXCR4 protein, humanEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanReceptors, CXCR4Diffuse large B-cell lymphomaEZH2; CXCR4Immune escapemiR-9Treg cell

Identifiers

PMID41286377
PMCPMC12644176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.